Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 Dose-finding in Resistant Hypertension
jRCT2031220454Completed
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of xxb750 in resistant hypertension (RH) (5 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean 24-hour systolic blood pressure at Week 12. Started Jan 2023; status: completed.
02
Drugs
xxb750
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on jRCT2031220454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220454.